African and European regulators are preparing trials for Bundibugyo Ebola vaccines and therapeutic options in the Democratic Republic of the Congo and Uganda. Reporting indicates multiple products are set to enter testing, including three vaccine candidates along with antibody therapies and antivirals. The trial preparations are aimed at outbreak response as the Bundibugyo strain continues to drive case risk in the region. For developers, the immediate relevance is clinical trial acceleration and trial design coordination across jurisdictions. Regulatory readiness in DRC and Uganda is a key operational step for developers, as it shapes enrollment speed, eligibility criteria, and the ability to generate interpretable efficacy and safety data under rapidly evolving outbreak conditions.